Feline leukemia virus group-specific antigen (p27) (p27)

The Feline leukemia virus group-specific antigen, commonly known as p27, is the primary structural protein of the FeLV capsid. It is encoded by the viral gag gene and is synthesized as part of a larger polyprotein precursor that is subsequently cleaved by viral proteases during maturation [1][2]. In infected cats, p27 is produced in significant quantities and is released into the bloodstream, making it the gold-standard biomarker for diagnosing active FeLV infection via ELISA or lateral flow assays [3]. While not a traditional small-molecule drug target, it is the central target for veterinary vaccines designed to elicit protective immunity against the virus [4]. Additionally, p27 is a focus for the development of therapeutic monoclonal antibodies aimed at reducing viral load in persistently infected felines. Understanding p27 levels is critical for managing feline populations, as its presence indicates high levels of viral replication and shedding [1][3].

Other names

p27p27gagFeLV p27Group-specific antigenCapsid protein p27Gag p27

Vaccines containing or expressing the p27 antigen stimulate the production of neutralizing antibodies and cell-mediated immunity to prevent persistent viremia [4]. Diagnostic assays utilize anti-p27 antibodies to capture and detect the antigen in blood or saliva, indicating active viral replication [3].